{{ variable.name }} : {{ variable.values[selectedVariantsIndex[variable_index]].name }}
Quantity:
Tesamorelin is a synthetic 44-amino-acid analog of growth hormone-releasing hormone (GHRH). Unlike direct growth hormone injections, it prompts the pituitary gland to release the body's natural growth hormone in physiological pulses.
Approved Medical Use
• HIV-Associated Lipodystrophy: Tesamorelin is FDA-approved (sold under the brand name Egrifta or Egrifta SV) to reduce excess visceral adipose tissue (deep abdominal fat around organs) in adults with HIV who experience antiretroviral-related lipodystrophy.
• Mechanism: It stimulates GHRH receptors, raising endogenous growth hormone and downstream insulin-like growth factor-1 (IGF-1) levels, which helps break down visceral fat stores.
Off-Label and Research Context
• Body Composition & General Fat Loss: While widely discussed off-label or prescribed in wellness clinics for general weight loss, anti-aging, improved sleep, or muscle retention, these uses are not FDA-approved.
• Reversibility: Clinical data show that stopping tesamorelin causes visceral fat levels to gradually return toward baseline, meaning the metabolic benefits require continuous adherence.
Administration & Safety
• Dosage Route: Administered via daily subcutaneous (under the skin) injection.
• Common Side Effects: Can include injection-site reactions (redness, itching, pain), joint or muscle aches (arthralgia, myalgia), peripheral edema (swelling), and shifts in blood sugar or IGF-1 levels.
• Precautions: It is contraindicated in patients with active malignancy, pituitary gland tumors, pregnancy, or known hypersensitivity, and requires medical supervision